Syngene reports better than expected revenues, margin pressure in Q1FY22: ICICI Direct

Key takeaways of recent quarter & conference call highlights

Syngene revenue from operations up 17 per cent in Q2FY22

The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations

Syngene sets up microbial facility as it expands biopharma-manufacturing capacity

It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies

Syngene Q1 FY22 revenue grows 41%

The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels

Syngene Q3 revenue up 13% to Rs. 585 Cr

EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.

Reliance Life Sciences appoints Siva Sankar Mahamkali as VP Biosimilars Manufacturing Operations

Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing

Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore

The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year

Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics

Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore

Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating

Strides appoints Yajuvendra Singh M R as VP - Digital Transformation

Singh previously served as Head of IT (Development and Manufacturing Services) at Syngene International Limited, Lead of IT Manufacturing at UPL, and AGM at The Hi-Tech Gears